SCP
BMY icon

Sender Company & Partners’s Bristol-Myers Squibb BMY Stock Holding History

Sender Company & Partners’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,800
Closed -$487K – 150
2025
Q3 		$487K Buy
+10,800
New +$504K 0.05% 263

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Sender Company & Partners's BMY Position: Q1 2024 in Review

Sender Company & Partners sold out of Bristol-Myers Squibb (BMY) in Q1 2024, closing a stake of 34,220 shares — an estimated $1.76M sold.

Sender Company & Partners first reported a position in BMY in Q4 2023 and held it in 1 quarter. The position peaked at $1.76M in Q4 2023. 2,331 funds tracked by Wall St. Rank hold BMY as of Q1 2024.

  • Sender Company & Partners reported no remaining Bristol-Myers Squibb position as of Q1 2024 after selling out during the quarter.
  • Sender Company & Partners sold 34,220 Bristol-Myers Squibb shares in Q1 2024, an estimated $1.76M.
  • Sender Company & Partners first reported a position in Bristol-Myers Squibb in Q4 2023 and held it in 1 quarter.
  • Sender Company & Partners's Bristol-Myers Squibb position peaked at $1.76M in Q4 2023.
  • 2,331 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2024.

Based on Sender Company & Partners's 13F filing for Q1 2024, filed 7 May 2024.